Tony Arulanandam
Chief Executive Officer Synaptimmune Therapeutics
Seminars
Wednesday 16th September 2026
Industry Leaders Panel Discussion:
8:30 am
- Using a SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats of bispecifics/ multispecifics compared to other drug modalities?
- In which cases are bispecifics/multispecifics being prioritized for autoimmune and immunology versus oncology?
- What datapoints are being assessed when it comes to bispecifics/multispecifics from a data package perspective for approval and backing from pharma?
- What data is lacking across the board for bispecifics/multispecifics?
- How are novel versus derisked targets being assessed, and what weighting/value is placed on safety and efficacy data, versus other data points?
- What stimulates interest around bispecific/multispecific assets versus platform technologies that generate target, construct and format menus?
Wednesday 16th September 2026
Conditionally Active CD3 & CD2 Costimulatory T-Cell Engagers for Solid- Tumor Indications
4:00 pm
- Conditional CD3 activation via hidden CD3 binder in TROY-Ig scaffold mitigates cytokine release
- CD2 costimulation and CD58 adhesion lowers the threshold for CD3 activation in T-cells
- CD2 costimulation and conditional CD3 activation TROY-Ig scaffold enables increased anti-tumor efficacy in solid tumor microenvironment
